Edgewise Therapeutics, Inc.’s EWTX share price has dipped by 5.98%, which has investors questioning if this is right time to ...

Edgewise Therapeutics is primarily focused on developing novel treatments for conditions such as Hypertrophic Cardiomyopathy (HCM), Duchenne Muscular Dystrophy (DMD), and Becker Muscular Dystrophy ...

April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from the Phase 2 ...

May 8, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (EWTX),, a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2025 and recent ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other top small cap stocks to buy with biggest upside potential. On April 24 ...

The last time I wrote about Edgewise Therapeutics, Inc. (NASDAQ:EWTX) it was in a Seeking Alpha article entitled "Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data." In the ...

Edgewise Therapeutics' hypertrophic cardiomyopathy (HCM) asset has resulted in “rapid and clinically meaningful” reductions of a measure of obstruction of the heart’s valves. The biotech has ...

Edgewise Therapeutics is primarily focused on developing novel treatments for conditions such as Hypertrophic Cardiomyopathy (HCM), Duchenne Muscular Dystrophy (DMD), and Becker Muscular Dystrophy ...